Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07061769

Helping Cancer Patients Manage Neuropathy Symptoms From Chemotherapy With a Low-Intensity, Low-Risk Cranial PEMF Device

The goal of this clinical trial is to examine a low-intensity, low-risk cranial PEMF device and its effectiveness with helping cancer patients manage neuropathy symptoms from chemotherapy. Eligible patients are individuals who have been diagnosed with chemotherapy-induced peripheral neuropathy or are experiencing pain due to chemotherapy and are eighteen to sixty. The main questions the study aims to answer are:

To examine whether the application of low intensity, low frequency PEMF (by the System for Heterogeneous Integrated magnetic Field Transmission (SHIFT)) results in a significant decrease in neuropathic pain intensity.

To examine if SHIFT results in a decrease of pain related interference and associated symptoms of CIPN.

Researchers will compare an active, treatment arm to a placebo, SHAM arm. Participants will be required to use the device once daily, fill out daily, weekly, and monthly surveys. They will have to do one blood draw at the beginning of the study and one at the end of the study.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Chemotherapy Induced Peripheral Neuropathy Chemotherapy Induced Neuropathic Pain Chemotherapy Induced Pain Neuropathy Chemotherapy Induced Peripheral Neuropathy (CIPN)

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hoag Spine Institute

Newport Beach, California, 92663, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Able to use smart phone and willing to receive text messages/emails
  • Has CIPN disorder/neuropathic pain related to chemotherapy
  • Able and willing to follow instructions
  • Not participated in any other clinical study within the past two months that may influence the results of this study

Exclusion criteria

  • History of seizures
  • Hydrocephalic
  • Had a change in medical therapy related to the treatment of neuropathy or chronic pain in the last fourteen days
  • Received repetitive transcranial magnetic stimulation (rTMS) in the last 60 days
  • Implanted device or metal in the brain
  • History of brain bleed in the last six months
  • History of suicidal behavior, bipolar disorder, schizophrenia
  • Active radiation over the scalp
  • Brain metastases
  • Currently participates in other neuropathic pain studies
  • Has any other medical condition that would prevent them from participating, including scalp wounds, hyperhidrosis, sensitive scalp, rash
  • Pregnant

Treatment and study plan

SHIFT

Device

SHIFT is a low intensity PEMF cranial device. It has been designated as a Non-Significant Risk device by the FDA.

Primary outcomes

  1. Decrease in Neuropathic Pain Intensity

    Time frame: 12 weeks

    Measured through scores in the Neuropathy Pain Scale. The Neuropathy Pain Scale uses a range a 0 to 10, with 0 being no pain/sensation and 10 being the most intense pain/sensation imaginable.

  2. Decrease in Numeric Pain Rating.

    Time frame: 12 weeks

    Measured through Numeric Pain Rating surveys. The numeric pain rating scale uses a range of 0 to 10, with 0 being no pain and 10 being the worst pain possible.

  3. Improvement in Neuropathic Pain Symptoms

    Time frame: 12 weeks

    Measured in weekly scores in the Neuropathic Pain Symptom Inventory. The inventory uses a scale of 1 to 10, with 1 being the no symptom and 10 being the worst symptom imaginable.

Secondary outcomes

  1. Decrease of pain-related interference

    Time frame: 12 weeks

    Examine if SHIFT results in a decrease of pain related interferences on a weekly basis. The PEG scale assesses how much pain interferes with weekly abilities on a scale of 0 to 10, with 0 being no interference/pain and ten being complete interference/worst pain imaginable.

  2. Decrease of pain-related stress

    Time frame: 12 weeks

    Examine if SHIFT results in a decrease of perceived stress related to pain on a weekly basis, using the perceived stress scale. The PSS examines how well patients have been able to sleep on a scale of 0 to 4 (0 being never and 4 being very often).

  3. Decrease of pain-related anxiety

    Time frame: 12 weeks

    Examine if SHIFT results in a decrease of anxiety related to pain as measured by the GAD-7. The GAD 7 uses a scale of 0 (not at all) to 3 (nearly every day) to measure how often a patient feels anxiety.

  4. Decrease of pain-related inflammatory markers

    Time frame: 12 weeks

    Examine if SHIFT results in a decrease of inflammatory markers in the blood, specifically a decrease in the presence of IL-6.

Sponsors and collaborators

Lead sponsor

FluxWear, INC

Industry

Collaborators

  • Hoag Memorial Hospital Presbyterian

Registry information

Official study title

Evaluating the Safety and Effectiveness of a Low Intensity Cranial PEMF Device in Improving Chemotherapy Induced Peripheral Neuropathy Symptoms

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 11, 2025
Registry last updated
Jul 11, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.